168 related articles for article (PubMed ID: 37274264)
1. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J
Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078
[TBL] [Abstract][Full Text] [Related]
4. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
Janku F; Bauer S; Shoumariyeh K; Jones RL; Spreafico A; Jennings J; Psoinos C; Meade J; Ruiz-Soto R; Chi P
ESMO Open; 2022 Aug; 7(4):100520. PubMed ID: 35753087
[TBL] [Abstract][Full Text] [Related]
7. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
Fung S; Shirley M
Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417
[TBL] [Abstract][Full Text] [Related]
8. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():883399. PubMed ID: 35847924
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
[TBL] [Abstract][Full Text] [Related]
10. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
Thirasastr P; Somaiah N
Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
Lim SY; Ferro-López L; Barquin E; Lindsay D; Thway K; Smith MJ; Benson C; Jones RL; Napolitano A
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473346
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
[TBL] [Abstract][Full Text] [Related]
13. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M
BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034
[TBL] [Abstract][Full Text] [Related]
15. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
[TBL] [Abstract][Full Text] [Related]
16. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
17. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
18. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
Symcox M; Somaiah N
Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
20. Progression of the tumor in a patient with a gastrointestinal stromal tumor with the
An Z; Tan M; Xia Y; Li Y; Fan L; Zhao Q; Zhang Z; Tan B; Liu Y; Ma Z; Wang D; Zhao X
J Gastrointest Oncol; 2022 Oct; 13(5):2620-2625. PubMed ID: 36388657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
